Merck taps celeb chef to deliver diabetes message to Hispanics

Carly Helfand Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck ...

AstraZeneca’s new antibiotic comes through in Phase III

Damian Garde AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot ...

Chikungunya vaccine shows antibody response in Phase I trial

Emily Mullin Following recent outbreaks in the Pacific and Caribbean, chikungunya virus has made its way to the U.S.–and drug developers have taken note of its continued spread. FierceBiotech ...

Bloomberg: Roche negotiating for rest of Chugai for $10B

Eric Palmer Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, more targeted buys. Of course what is targeted ...

Allergan bets up to $588M on Taris’ bladder candidate

Damian Garde Amid its fight to stave off a hostile takeover, Botox maker Allergan is making a buy of its own, trading up to $ 587.5 million for a midstage bladder drug from the biotech ...

Prefer a Swiss tax rate? Basilea chief says he’s ready to parley

John Carroll Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick ...

Survival miss for Amgen’s Kyprolis may hurt approval chances in Europe

Carly Helfand A Phase III late-stage myeloma miss for Amgen's Kyprolis didn't shock analysts, who said the failure was more or less expected when the company announced trial ...

Another Israeli biotech braves choppy IPO waters

John Carroll The latest batch of Israeli biotechs to hit Nasdaq hasn't been doing so well. But that hasn't deterred Foamix Pharmaceuticals from joining the tail end of the big ...

Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniors

Carly Helfand Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. ...

Takeda preps for ‘stringent’ R&D as a new boss takes the reins

Damian Garde Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas ...

Roche persuades U.S. judge to toss $2M Accutane verdict

Carly Helfand Roche has emerged victorious in its quest to reverse a $ 2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne med Accutane ...

Biota tanks as its flu drug comes up empty in Phase II

Damian Garde Biota Pharmaceuticals' slow trip downward continued Friday as the company disclosed that its its lead program, a flu treatment called laninamivir octanoate, failed ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS